Mural Oncology
Caroline J Loew, PhD is currently the CEO of Mural Oncology. Previously, Caroline J served as a Strategic Advisor | Consultant and President and CEO at Glympse Bio. Before that, Caroline J held the position of Vice President, Head of R&D Strategy and Planning at Bristol-Myers Squibb and Vice President, Late Lifecycle Management and Loss of Exclusivity Center of Excellence at Merck. Caroline has also worked as the Vice President of Customer Value and Health Technology Assessment at Merck and as a Senior Vice President at PhRMA. Caroline J holds a PhD in Organic Chemistry and a Bachelor of Science in Chemistry from Imperial College London.
Mural Oncology
2 followers
We know that drug development is both an art and a science. The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us. Our mission is simple, to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living. Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies. We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective. Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)